Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul Linh Nguyen, M.D.

Co-Author

This page shows the publications co-authored by Paul Nguyen and Clair Beard.
Connection Strength

8.714
  1. Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2018 10; 41(10):953-959.
    View in: PubMed
    Score: 0.206
  2. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523.
    View in: PubMed
    Score: 0.198
  3. Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e96-e97.
    View in: PubMed
    Score: 0.196
  4. Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. Eur Urol. 2018 04; 73(4):e100-e101.
    View in: PubMed
    Score: 0.193
  5. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017 Dec 15; 123(24):4832-4840.
    View in: PubMed
    Score: 0.191
  6. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol. 2018 02; 73(2):262-270.
    View in: PubMed
    Score: 0.189
  7. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2019 01; 5(1):69-76.
    View in: PubMed
    Score: 0.188
  8. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104.
    View in: PubMed
    Score: 0.187
  9. Racial Disparities in Prostate Cancer Outcome among Prostate-Specific Antigen Screening Eligible Populations in the United States. Ann Oncol. 2017 Feb 08.
    View in: PubMed
    Score: 0.184
  10. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 06; 20(2):186-192.
    View in: PubMed
    Score: 0.183
  11. Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):140-147.
    View in: PubMed
    Score: 0.183
  12. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3.
    View in: PubMed
    Score: 0.180
  13. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700.
    View in: PubMed
    Score: 0.178
  14. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377.
    View in: PubMed
    Score: 0.177
  15. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8.
    View in: PubMed
    Score: 0.173
  16. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12.
    View in: PubMed
    Score: 0.172
  17. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy. 2016 Feb; 8(1):1-6.
    View in: PubMed
    Score: 0.172
  18. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90.
    View in: PubMed
    Score: 0.170
  19. Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22.
    View in: PubMed
    Score: 0.168
  20. Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32.
    View in: PubMed
    Score: 0.167
  21. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85.
    View in: PubMed
    Score: 0.166
  22. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35.
    View in: PubMed
    Score: 0.165
  23. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8.
    View in: PubMed
    Score: 0.163
  24. Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy. 2015 Jul-Aug; 14(4):511-6.
    View in: PubMed
    Score: 0.162
  25. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9.
    View in: PubMed
    Score: 0.160
  26. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16.
    View in: PubMed
    Score: 0.160
  27. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406.
    View in: PubMed
    Score: 0.158
  28. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65.
    View in: PubMed
    Score: 0.157
  29. Incidence and determinants of 1-month mortality after cancer-directed surgery. J Clin Oncol. 2014 Oct 20; 32(30_suppl):282.
    View in: PubMed
    Score: 0.157
  30. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13.
    View in: PubMed
    Score: 0.156
  31. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9.
    View in: PubMed
    Score: 0.153
  32. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92.
    View in: PubMed
    Score: 0.153
  33. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy. 2014 Sep-Oct; 13(5):442-9.
    View in: PubMed
    Score: 0.152
  34. Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8.
    View in: PubMed
    Score: 0.152
  35. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91.
    View in: PubMed
    Score: 0.152
  36. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95.
    View in: PubMed
    Score: 0.152
  37. Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21.
    View in: PubMed
    Score: 0.151
  38. Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes. Brachytherapy. 2014 Mar-Apr; 13(2):152-6.
    View in: PubMed
    Score: 0.144
  39. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):415-21.
    View in: PubMed
    Score: 0.142
  40. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer. 2013 Aug 01; 119(15):2771-7.
    View in: PubMed
    Score: 0.141
  41. Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. J Clin Oncol. 2013 Feb 20; 31(6_suppl):232.
    View in: PubMed
    Score: 0.140
  42. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol. 2012 Oct; 188(4):1151-6.
    View in: PubMed
    Score: 0.135
  43. High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature. Brachytherapy. 2013 Jan-Feb; 12(1):77-83.
    View in: PubMed
    Score: 0.132
  44. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012 Jun; 187(6):2068-73.
    View in: PubMed
    Score: 0.131
  45. Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):383-9.
    View in: PubMed
    Score: 0.130
  46. Long-term results of MRI-guided partial prostate brachytherapy for favorable-risk prostate cancer: Implications for focal therapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):114.
    View in: PubMed
    Score: 0.130
  47. Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):172-178.
    View in: PubMed
    Score: 0.127
  48. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):1411-6.
    View in: PubMed
    Score: 0.124
  49. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer. 2011 Jan 15; 117(2):406-13.
    View in: PubMed
    Score: 0.118
  50. Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1318-22.
    View in: PubMed
    Score: 0.116
  51. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 2010 Feb 01; 116(3):610-5.
    View in: PubMed
    Score: 0.113
  52. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1046-52.
    View in: PubMed
    Score: 0.111
  53. Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol. 2009 May 20; 27(15_suppl):5129.
    View in: PubMed
    Score: 0.108
  54. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948.
    View in: PubMed
    Score: 0.055
  55. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer. 2018 09 01; 124(17):3528-3535.
    View in: PubMed
    Score: 0.051
  56. Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer. 2014; 2014:912943.
    View in: PubMed
    Score: 0.037
  57. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72.
    View in: PubMed
    Score: 0.037
  58. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55.
    View in: PubMed
    Score: 0.035
  59. Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):82.
    View in: PubMed
    Score: 0.035
  60. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6.
    View in: PubMed
    Score: 0.034
  61. Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU Int. 2012 Nov; 110(9):1252-6.
    View in: PubMed
    Score: 0.033
  62. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.